Medication info

Telmisartan/Rosuvastatin 40/5 mg

Prescription medicationTabletOralExpired
Ingredient · strength
Telmisartan›40mg / 1 tabletRosuvastatin Calcium›5.2mg / 1 tablet
Manufacturer / importer
Youngjin Pharmaceutical Co., Ltd.
Appearance
Bright pink oval film-coated tablet
Packaging
30 tablets/box [10 tablets/PTP*3]
Approval status
Expired

MFDS item code 201906983 · Approved 2019.09.30

This product's status changed to Expired on 2025.10.31. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of dyslipidemia and hypertension, inhibition of atherosclerosis progression, and prevention of cardiovascular disease
Who takes it
Adults
Adult dose
This medicinal product should be administered only to adults. The dose should be individualized for each patient based on the efficacy and tolerability of each component, telmisartan/rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg of telmisartan orally once daily; depending on the patient, 20 mg once daily may be effective. If necessary, the dose may be increased to 80 mg once daily. When this medicinal product is coadministered with a thiazide diuretic such as hydrochlorothiazide, an additional blood pressure-lowering effect is observed. When the dose is increased, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after the start of treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose of this medicinal product is 80 mg orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg has not been established. When initiating treatment with this medicinal product to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive agents may be required. 3. Patients with hepatic impairment Administer with caution to patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicinal product, and should continue it throughout the treatment period. This medicinal product may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, and most patients are controlled at this dose. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering this medicinal product at a dose of 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Assessment of renal function should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicinal product to patients with active liver disease. 5. Race: Because systemic exposure to this medicinal product is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40 milligrams dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of this medicinal product at a dose of 40 milligrams is contraindicated in some of these patients. For patients taking telmisartan and rosuvastatin concomitantly, they may switch to this medicinal product (a combination product containing the same amount of each active ingredient) for convenience.

Ingredients

Manufacturer
Youngjin Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of dyslipidemia and hypertension, inhibition of atherosclerosis progression, and prevention of cardiovascular disease

  • Essential hypertension
  • coronary artery disease
  • peripheral artery disease
  • stroke
  • transient ischemic attack
  • clinical evidence of damage to end organs
  • high-risk diabetes
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • complex hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
View approved original text

This medication is used for patients who require simultaneous administration of both Telmisartan and Rosuvastatin. Telmisartan helps reduce the risks of myocardial infarction, stroke, and cardiovascular death in patients over 55 years of age with essential hypertension. Rosuvastatin Calcium is used for the treatment of hypercholesterolemia and dyslipidemia and is used as an adjunct treatment when diet and exercise are insufficient. It also contributes to reducing the risk of stroke, myocardial infarction, and vascular revascularization in patients at high risk of cardiovascular disease. The combination of both drugs effectively manages blood pressure and cholesterol, thereby reducing the risk of cardiovascular disease and improving patient health.

How to take

Adult dose

This medicinal product should be administered only to adults. The dose should be individualized for each patient based on the efficacy and tolerability of each component, telmisartan/rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg of telmisartan orally once daily; depending on the patient, 20 mg once daily may be effective. If necessary, the dose may be increased to 80 mg once daily. When this medicinal product is coadministered with a thiazide diuretic such as hydrochlorothiazide, an additional blood pressure-lowering effect is observed. When the dose is increased, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after the start of treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose of this medicinal product is 80 mg orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg has not been established. When initiating treatment with this medicinal product to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive agents may be required. 3. Patients with hepatic impairment Administer with caution to patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicinal product, and should continue it throughout the treatment period. This medicinal product may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, and most patients are controlled at this dose. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering this medicinal product at a dose of 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Assessment of renal function should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicinal product to patients with active liver disease. 5. Race: Because systemic exposure to this medicinal product is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40 milligrams dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of this medicinal product at a dose of 40 milligrams is contraindicated in some of these patients. For patients taking telmisartan and rosuvastatin concomitantly, they may switch to this medicinal product (a combination product containing the same amount of each active ingredient) for convenience.

Precautions

This medication may cause serious harm to the fetus and newborn during pregnancy, so if pregnancy is confirmed, discontinue use immediately. Women of childbearing potential should use appropriate contraception, and this drug should not be administered to pregnant or breastfeeding women. Patients with severely impaired liver or kidney function, certain genetic diseases, and those allergic to this drug or its components should avoid using it. Caution is needed for the elderly, patients with hyperkalemia, and those with mildly impaired liver function, and regular monitoring as directed by a physician is necessary. If symptoms such as myalgia or muscle weakness occur, consult a doctor immediately, and in severe cases, discontinuation of the drug may be necessary. This drug may interact with other medications, so be sure to inform your doctor or pharmacist of any other medications being taken. In cases of overdose, symptoms such as hypotension, dizziness, and acute renal failure may occur; if suspected, visit a medical facility immediately. Care is needed when driving or operating machinery as drowsiness or dizziness may occur. Store out of reach of children and do not transfer to another container for safety.

Side effects

Headache, orthostatic dizziness, sleep paralysis, increased blood pressure, decreased blood pressure, hypotension, elevated ALT, dysuria, rhinitis, oropharyngeal discomfort, pulmonary disease, gastrointestinal disorders, hemorrhoids, skeletal pain, osteoporosis, sensory impairment, movement disorders, atherosclerosis, frequency of urination, tinnitus, hearing loss, halitosis, fatty liver, upper respiratory infection, urinary tract infection, sepsis, anemia, thrombocytopenia, eosinophilia, hypersensitivity, anaphylactic reaction, hyperkalemia, hypoglycemia, depression, insomnia, anxiety, syncope, visual disturbances, dizziness, bradycardia, tachycardia, dyspnea, abdominal pain, diarrhea, dyspepsia, abdominal bloating, vomiting, abdominal discomfort, dry mouth, abnormal liver function, liver impairment, increased sweating, itching, rash, erythema, angioedema, drug rash, toxic skin rash, eczema, urticaria, myalgia, low back pain, muscle cramps, arthralgia, limb pain, tendon pain, acute renal failure, chest pain, weakness, influenza-like illness, increased serum creatinine, increased serum uric acid, elevated liver enzymes, increased serum CK, decreased hemoglobin, facial spasms, sensory disturbances, paralysis, cough, hyperventilation, pneumonia, flushing, erectile dysfunction, loss of appetite, arrhythmia, weakness, edema, decreased libido, facial edema, alopecia, conjunctivitis, tinnitus, petechiae, headache, facial spasms, sensory disturbances, paralysis, cough, hyperventilation, pneumonia, flushing, erectile dysfunction, loss of appetite, arrhythmia, weakness, edema, decreased libido, facial edema, rash, alopecia, conjunctivitis, tinnitus, petechiae, angioedema, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms syndrome, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disturbances, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, memory decline, amnesia, dissociative state, memory impairment, confusion, severe muscle weakness, ocular myopathy, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, increased ALT, chest pain, cough, myalgia, increased CK, constipation, increased AST, weakness, arthralgia, fatigue, numbness, sensory disturbances, chest discomfort, nausea, abdominal pain, diarrhea, loss of appetite, abdominal bloating, abnormal liver function tests, syncope, systemic pain, muscle cramps, gout, erectile dysfunction, arrhythmia, acute renal failure, oliguria, thrombocytopenia, increased serum creatinine, hypotension, tachycardia, bradycardia, dizziness, acute renal failure, shock, blood pressure drop, loss of consciousness, liver dysfunction, jaundice, symptoms resembling anaphylaxis, interstitial pneumonia, rhabdomyolysis, palpitations, fatigue, nausea, insufficient effect

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it should be stored in a sealed container. It is best to maintain the storage temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

Bright pink oval film-coated tablet

Package unit

30 tablets/box [10 tablets/PTP*3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.